HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $180 price target.
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.